The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (MDS).